|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 177,600.00 KRW | +3.14% |
|
+1.02% | +3.03% |
| 07-24 | Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55 | MT |
| 07-24 | Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CELLTRION, INC. | Other Biotechnology & Medical Research | +3.14% | +1.02% | +3.03% | +3.37% | -19.55% | 27.89B |  |  | |
- Stock Market
- Stocks
- A068270 Stock
- Charts Celltrion, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
